1YG0.F Mendus AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.4310 EUR
Close of Nov 11, 2026
0.3470 0.6530
Market cap
EUR 27.4M
P/E
-
P/B
0.66x
ROE
-15.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 1YG0.F undervalued?

Graham number

The Graham number of Mendus AB (publ) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mendus AB (publ) fundamental analysis

No fundamental analysis for Mendus AB (publ) yet.

Mendus AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mendus AB (publ)

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to s…

Full company profile